IGF-1 LR3 differs from regular IGF-1 in that it has an additional 13 amino acids on its N-terminal end, which increases its half-life and bioavailability in the body
Common side effects include gastrointestinal issues like nausea, vomiting, abdominal pain, and digestive discomfort, while fatigue, headache, and dizziness are less frequent
Subcutaneous injections like semaglutide occasionally trigger localized itching, redness, or mild swelling at the injection site
This structural damage is irreversible and immediate
It serves as a fuel source for the cells lining the intestines, supporting their optimal function and promoting gut barrier integrity
Metabolic-dysfunction-associated steatotic liver diseaseits pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments